EU adds another rare blood condition as side effect of AstraZeneca shot By Reuters
By Pushkala Aripaka and Ludwig Burger (Reuters) - Europe's drug regulator on Friday identified another rare blood condition as a potential side effect of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots. The European Medicines Agency's (EMA) safety committee said that capillary leak syndrome must be added as a new side effect to labelling on AstraZeneca's vaccine, known as Vaxzevria. People who had previously sustained the condition, where fluids leak from the smallest blood vessels causing swelling and a drop in blood pressure,...
Continue reading